| Assessment Status | Rapid Review Complete |
| HTA ID | 21055 |
| Drug | Relugolix with estradiol and norethisterone acetate |
| Brand | Ryeqo® |
| Indication | Is indicated for moderate to severe symptoms of uterine fibroids in adult women of reproductive age. |
| Assessment Process | |
| Rapid review commissioned | 01/02/2022 |
| Rapid review completed | 03/02/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that relugolix CT not be considered for reimbursement at the submitted price *. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.